These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 25270632)

  • 1. PA-824 is as effective as isoniazid against latent tuberculosis infection in C3HeB/FeJ mice.
    Dutta NK; Karakousis PC
    Int J Antimicrob Agents; 2014 Dec; 44(6):564-6. PubMed ID: 25270632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel regimens identified in mice for treatment of latent tuberculosis infection in contacts of patients with multidrug-resistant tuberculosis.
    Lanoix JP; Betoudji F; Nuermberger E
    Antimicrob Agents Chemother; 2014; 58(4):2316-21. PubMed ID: 24492372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis.
    Lanoix JP; Betoudji F; Nuermberger E
    Antimicrob Agents Chemother; 2016 Feb; 60(2):1091-6. PubMed ID: 26643352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions.
    Harper J; Skerry C; Davis SL; Tasneen R; Weir M; Kramnik I; Bishai WR; Pomper MG; Nuermberger EL; Jain SK
    J Infect Dis; 2012 Feb; 205(4):595-602. PubMed ID: 22198962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fighting tuberculosis by drugs targeting nonreplicating
    Iacobino A; Piccaro G; Giannoni F; Mustazzolu A; Fattorini L
    Int J Mycobacteriol; 2017; 6(3):213-221. PubMed ID: 28776518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection.
    Zhang T; Li SY; Williams KN; Andries K; Nuermberger EL
    Am J Respir Crit Care Med; 2011 Sep; 184(6):732-7. PubMed ID: 21659613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis.
    Lanoix JP; Lenaerts AJ; Nuermberger EL
    Dis Model Mech; 2015 Jun; 8(6):603-10. PubMed ID: 26035868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.
    Rosenthal IM; Tasneen R; Peloquin CA; Zhang M; Almeida D; Mdluli KE; Karakousis PC; Grosset JH; Nuermberger EL
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4331-40. PubMed ID: 22664964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Improved Resistance Potential of a Cofactor-Independent InhA Inhibitor of Mycobacterium tuberculosis in the C3HeB/FeJ Mouse Model.
    Robertson GT; Ektnitphong VA; Scherman MS; McNeil MB; Dennison D; Korkegian A; Smith AJ; Halladay J; Carter DS; Xia Y; Zhou Y; Choi W; Berry PW; Mao W; Hernandez V; Alley MRK; Parish T; Lenaerts AJ
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model.
    Hu Y; Pertinez H; Ortega-Muro F; Alameda-Martin L; Liu Y; Schipani A; Davies G; Coates A
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4778-85. PubMed ID: 27216065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential Mycobacterium bovis BCG vaccine-derived efficacy in C3Heb/FeJ and C3H/HeOuJ mice exposed to a clinical strain of Mycobacterium tuberculosis.
    Henao-Tamayo M; Obregón-Henao A; Creissen E; Shanley C; Orme I; Ordway DJ
    Clin Vaccine Immunol; 2015 Jan; 22(1):91-8. PubMed ID: 25392011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isoniazid and rifapentine treatment effectively reduces persistent M. tuberculosis infection in macaque lungs.
    Sharan R; Ganatra SR; Singh DK; Cole J; Foreman TW; Thippeshappa R; Peloquin CA; Shivanna V; Gonzalez O; Day CL; Gandhi NR; Dick EJ; Hall-Ursone S; Mehra S; Schlesinger LS; Rengarajan J; Kaushal D
    J Clin Invest; 2022 Sep; 132(18):. PubMed ID: 35862216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of a Long-Acting Injectable Bedaquiline Formulation in a Paucibacillary Mouse Model of Latent Tuberculosis Infection.
    Kaushik A; Ammerman NC; Tyagi S; Saini V; Vervoort I; Lachau-Durand S; Nuermberger E; Andries K
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis.
    Nuermberger E; Rosenthal I; Tyagi S; Williams KN; Almeida D; Peloquin CA; Bishai WR; Grosset JH
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2621-5. PubMed ID: 16870750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis.
    Tasneen R; Tyagi S; Williams K; Grosset J; Nuermberger E
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3664-8. PubMed ID: 18694943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapeutic efficacy of thioridazine as an adjunct drug in a murine model of latent tuberculosis.
    Singh A; Sharma S
    Tuberculosis (Edinb); 2014 Dec; 94(6):695-700. PubMed ID: 25305001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delamanid Kills Dormant Mycobacteria
    Chen X; Hashizume H; Tomishige T; Nakamura I; Matsuba M; Fujiwara M; Kitamoto R; Hanaki E; Ohba Y; Matsumoto M
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models.
    Lenaerts AJ; Gruppo V; Marietta KS; Johnson CM; Driscoll DK; Tompkins NM; Rose JD; Reynolds RC; Orme IM
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2294-301. PubMed ID: 15917524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis.
    Nikonenko BV; Samala R; Einck L; Nacy CA
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4550-5. PubMed ID: 15561824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH.
    Iacobino A; Giannoni F; Pardini M; Piccaro G; Fattorini L
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31010861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.